{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:27:49Z","timestamp":1790800069819,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.bcmd.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,1,17]],"date-time":"2015-01-17T02:05:51Z","timestamp":1421460351000},"page":"307-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard"],"prefix":"10.1016","volume":"54","author":[{"given":"Mina","family":"Mirzaian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma E.","family":"Donker-Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marri","family":"Verhoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman S.","family":"Overkleeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf G.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.01.006_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.bcmd.2015.01.006_bb0010","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bcmd.2015.01.006_bb0015","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bcmd.2015.01.006_bb0020","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.01.006_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2015.01.006_bb0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.bcmd.2015.01.006_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.bcmd.2015.01.006_bb0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigationaloral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcmd.2015.01.006_bb0055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcmd.2015.01.006_bb0065","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcmd.2015.01.006_bb0070","doi-asserted-by":"crossref","first-page":"e79732","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2015.01.006_bb0075","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcmd.2015.01.006_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bcmd.2015.01.006_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/path.4227","article-title":"B cell lymphoma and myeloma in murine Gaucher's disease","volume":"231","author":"Pavlova","year":"2013","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.bcmd.2015.01.006_bb0090","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasmalyso-Gb\u2083-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.bcmd.2015.01.006_bb0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1432-1033.1985.tb09058.x","article-title":"The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen","volume":"150","author":"Aerts","year":"1985","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.bcmd.2015.01.006_bb0120","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.bcmd.2015.01.006_bb0125","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.bcmd.2015.01.006_bb0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/0929867311320020008","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0006-291X(73)90916-9","article-title":"Deficiency of glucosylsphingosine: beta-glucosidase in Gaucher disease","volume":"54","author":"Raghavan","year":"1973","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1399-0004.1985.tb00229.x","article-title":"Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants","volume":"27","author":"Nilsson","year":"1985","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0150","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2015.01.006_bb0155","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1194\/jlr.M017178","article-title":"Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice","volume":"52","author":"Durant","year":"2011","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.bcmd.2015.01.006_bb0160","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cbic.201402153","article-title":"The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family","volume":"15","author":"Kov\u00e1\u010dik","year":"2014","journal-title":"Chembiochem"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:26Z","timestamp":1761049826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1079979615000261"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.01.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}